Physician profile
Will Rutland
NPI 1194256271
$1,956.39
in general payments reported to CMS, 2019-2025
18 companies · $681 in 2025
The $681 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $286 · 2023: $540 · 2024: $450 · 2025: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,670.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $288.39 | 2022-2024 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $229.24 | 2024-2025 | Ingrezza |
| Abbvie INC. | $196.14 | 2022-2024 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $178.62 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $175.18 | 2022-2025 | Auvelity |
| Lundbeck LLC | $171.67 | 2022-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $149.60 | 2023-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $131.69 | 2022-2024 | Caplyta |
| Indivior INC. | $95.43 | 2025 | Sublocade |
| E.R. Squibb & Sons, L.L.C. | $57.98 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $52.27 | 2023 | Spravato |
| Corium, LLC | $43.09 | 2025 | Azstarys |
| Bausch Health US, LLC | $39.11 | 2023 | Aplenzin |
| Tris Pharma INC | $38.86 | 2025 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $33.75 | 2025 | Fanapt |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $29.59 | 2022 | |
| Supernus Pharmaceuticals, INC. | $29.03 | 2025 | Qelbree |
| Vertical Pharmaceuticals, LLC | $16.75 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Will Rutland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.